Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Tangpeerachaikul · SciRah

Researcher profile · Semantic Scholar

A. Tangpeerachaikul

Share profile

A. Tangpeerachaikul — researcher profile on SciRah

h-index: 6
Works: 26
Citations: 647

Most-cited papers

Mediator Kinase Inhibition Further Activates Super-Enhancer Associated Genes in AML
H. Pelish, Brian B Liau, I. Nitulescu, A. Tangpeerachaikul +22 more
2015Nature362 citations Open access
Semantic Scholar
Identification of Mediator kinase substrates in human cells using cortistatin A and quantitative phosphoproteomics
Z. Poss, C. Ebmeier, Aaron Odell, A. Tangpeerachaikul +6 more
2016Cell Reports142 citations Open access
Semantic Scholar
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
Jessica J. Lin, J. C. Horan, A. Tangpeerachaikul, A. Swalduz +24 more
2024Cancer Discovery51 citations Open access
Semantic Scholar
NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations
A. Drilon, J. Horan, A. Tangpeerachaikul, B. Besse +20 more
2022Cancer Discovery38 citations Open access
Semantic Scholar
Abstract 1468: NUV-655 (NVL-655) is a selective, brain-penetrant ALK inhibitor with antitumor activity against the lorlatinib-resistant G1202R/L1196M compound mutation
H. Pelish, A. Tangpeerachaikul, N. Kohl, J. Porter +2 more
2021Experimental and Molecular Therapeutics24 citations
Semantic Scholar
Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
A. Tangpeerachaikul, S. Mente, Joseph M. Magrino, Franklin Gu +2 more
2025Molecular Cancer Therapeutics7 citations Open access
Semantic Scholar
Peer Review #1 of "Synthesis and biological evaluation of small molecule modulators of CDK8/Cyclin C complex with phenylaminoquinoline scaffold (v0.1)"
M. Al-Sanea, A. Abdelazem, M. Al-Sanea, B. Park +186 more
20205 citations Open access
Semantic Scholar
Abstract 1465: NUV-520 (NVL-520) is a brain-penetrant and highly selective ROS1 inhibitor with antitumor activity against the G2032R solvent front mutation
H. Pelish, A. Tangpeerachaikul, N. Kohl, J. Porter +2 more
2021Experimental and Molecular Therapeutics4 citations
Semantic Scholar
Abstract 1979: Preclinical characterization of NVL-330, a selective and brain penetrant HER2 tyrosine kinase inhibitor with broad activity on HER2 oncogenic alterations
Yu-Ting Sun, K. L. Andrews, A. Tangpeerachaikul, Tuan M. Nguyen +4 more
2024Cancer Research3 citations
Semantic Scholar
EP08.02-020 Preclinical Activity of NVL-655 in a Patient-Derived NSCLC Model with Lorlatinib-Resistant ALK G1202R/T1151M Mutation
H. Mizuta, L. Bigot, A. Tangpeerachaikul, H. Pelish +1 more
2022Journal of Thoracic Oncology3 citations Open access
Semantic Scholar
Abstract 3337: Preclinical activity of NVL-655 in ALK-driven cancer models beyond non-small cell lung cancer
A. Tangpeerachaikul, L. Bigot, L. Friboulet, H. Pelish
2022Cancer Research2 citations
Semantic Scholar
Preclinical activity of NVL-655 in patient-derived models of ALK cancers, including those with lorlatinib-resistant G1202R/L1196M compound mutation
T. Fujino, L. Nguyen, S. Yoda, M. Yu +9 more
2022European Journal of Cancer2 citations Open access
Semantic Scholar
Abstract 1729: Mutagenesis screens support potential best-in-class profile for neladalkib (NVL-655), a brain-penetrant and TRK-sparing ALK inhibitor
A. Tangpeerachaikul, H. Pelish
2025Cancer Research1 citations
Semantic Scholar
Abstract LB182: Mutagenesis screens support potential best-in-class profile for selective, brain-penetrant, and TRK-sparing ROS1 inhibitor NVL-520
A. Tangpeerachaikul, Franklin Gu, H. Pelish
2024Cancer Research1 citations
Semantic Scholar
Abstract 4022: Preclinical intracranial activity of NVL-655 in an alectinib-resistant patient-derived model harboring EML4-ALK fusion with G1202R mutation
J. Lee, Mi-Ra Yu, Mi R. Yun, You Won Lee +5 more
2023Cancer Research1 citations
Semantic Scholar
Abstract 3336: Preclinical activity of NVL-520 in ROS1-driven cancer models with diverse fusion partners and kinase-domain mutations
A. Tangpeerachaikul, Clare Keddy, K. Nicholson, M. Davare +1 more
2022Cancer Research1 citations
Semantic Scholar
NVL-330 is a selective, brain-penetrant inhibitor of oncogenic HER2 exon 20 insertion mutations in preclinical models
K. L. Andrews, Y. Sun, B. Gerard, A. Tangpeerachaikul +6 more
2022European Journal of Cancer1 citations Open access
Semantic Scholar
Abstract P247: Evaluating TRKB activity of novel preclinical brain-penetrant ROS1 and ALK inhibitors
A. Tangpeerachaikul, J. C. Horan, H. Pelish
2021Poster Presentations - Proffered Abstracts1 citations
Semantic Scholar
Abstract LB366: Zidesamtinib has differentiated preclinical brain penetrance and intracranial activity compared to other ROS1 inhibitors
A. Tangpeerachaikul, J. C. Horan, H. Pelish
2026Cancer Research0 citations
Semantic Scholar
Abstract 5616: Crystal structure of drug-resistant ROS1 G2032R in complex with zidesamtinib, a clinical-stage ROS1 inhibitor with best-in-class potential
Joseph M. Magrino, A. Tangpeerachaikul, H. Pelish, S. Mente
2025Cancer Research0 citations
Semantic Scholar
Abstract B057: Preclinical intracranial activity of NVL-330, a selective HER2 tyrosine kinase inhibitor
Yu-Ting Sun, K. L. Andrews, A. Tangpeerachaikul, Michael J. Walsh +3 more
2025Molecular Cancer Therapeutics0 citations
Semantic Scholar
8P Profiling of zidesamtinib and other ROS1 inhibitors in an intracranial CD74-ROS1 G2032R preclinical model
A. Tangpeerachaikul, H. Pelish
2024Annals of Oncology0 citations Open access
Semantic Scholar
Nuvalent Presents New Preclinical Data Supporting Potential Best-in-Class Profile for ALK-Selective Inhibitor NVL-655 at IASLC 2022 World Conference on Lung Cancer Annual Meeting-Aug 5, 2022
A. Tangpeerachaikul, H. Pelish, S. Gadgeel, M. Johnson +9 more
20220 citations
Semantic Scholar
Abstract P249: Preclinical antitumor activity of NVL-520 in patient-derived models harboring ROS1 fusions, including G2032R solvent front mutation
Amit M. Deshpande, S. Yoda, A. Tangpeerachaikul, N. Kohl +3 more
2021Poster Presentations - Proffered Abstracts0 citations
Semantic Scholar
Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual
A. Tangpeerachaikul, H. Pelish, Joseph M. Magrino, S. Mente
0 citations
Semantic Scholar
Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting
Yu-Ting Sun, K. L. Andrews, A. Tangpeerachaikul, Tuan M. Nguyen +5 more
0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

H. Pelish×26
Invite
H. Pelish — researcher profile on SciRah
J. C. Horan×8
Invite
J. C. Horan — researcher profile on SciRah
M. D. Shair×6
Invite
M. D. Shair — researcher profile on SciRah
S. Mente×6
Invite
S. Mente — researcher profile on SciRah

×5

Invite

N. Kohl — researcher profile on SciRah

Invite

Yu-Ting Sun — researcher profile on SciRah

Invite

N. E. Kohl — researcher profile on SciRah

Invite

L. Bigot — researcher profile on SciRah

Invite

J. Porter — researcher profile on SciRah

L. Friboulet×4

Invite

L. Friboulet — researcher profile on SciRah

Invite

J. Horan — researcher profile on SciRah

K. L. Andrews×4

Invite

K. L. Andrews — researcher profile on SciRah